Virbac stock trades steady as animal health group digests strong 2024 revenue growth

Virbac stock is backed by solid 2024 figures from the French animal health company Virbac S.A. (ISIN FR0000031577), with investors focusing on revenue growth, profitability and the group’s positioning in companion animal and livestock treatments.

Revenue up in 2024

Virbac S.A. is a global animal health group headquartered in Carros near Nice in France, specializing in veterinary pharmaceuticals, vaccines and nutrition for companion animals and livestock. According to the company’s published 2024 financial information, Virbac generated annual revenue of approximately EUR 1.4 billion in fiscal 2024, representing an increase compared with the prior year’s level around EUR 1.3 billion. This implies year on year revenue growth in the mid to high single-digit percent range, underlining that the group continued to expand its top line despite a mixed macroeconomic and farm-price environment.

Within this revenue performance, Virbac reported that its companion animal segment – which covers products for dogs, cats and other pets – remained the largest contributor, accounting for a clear majority of group sales. The company indicated that companion animal revenue rose meaningfully compared with fiscal 2023, supported by demand for dermatology, dental care and parasiticide ranges across Europe and North America. Livestock revenue, addressing cattle, swine and poultry markets among others, also grew versus the previous year, albeit at a more moderate pace reflecting uneven farm-sector dynamics and differing regional growth profiles.

Virbac’s geographic footprint is diversified, with Europe, North America, Latin America and Asia-Pacific all contributing to the revenue base. The company highlighted that Europe remained a key region in 2024, with France and other major European markets delivering stable to growing sales performance, while Latin America and Asia-Pacific provided incremental growth on top of the developed-market base. This spread of activities is an important factor for investors assessing Virbac stock, as it helps to mitigate exposure to any single regional regulatory or demand shock in the animal health industry.

Margin and earnings performance

Beyond revenue, profitability metrics in 2024 were an important focus. Virbac has historically targeted an EBITDA margin in the mid to high teens, reflecting the value-added nature of veterinary pharmaceuticals and the need to invest in research and development as well as commercial infrastructure. In fiscal 2024, the company reported an EBITDA margin in this typical range, slightly higher than the prior year’s margin, indicating some operating leverage on the growing revenue base and disciplined cost control despite inflationary pressures in manufacturing and logistics.

Net income attributable to the group for fiscal 2024 was reported in the low to mid EUR hundreds of millions, up compared with fiscal 2023, underscoring that Virbac translated revenue expansion and margin improvements into bottom-line growth. Earnings per share (EPS), calculated on the company’s outstanding share count, accordingly increased year on year. From an investor perspective, such earnings progress is central for Virbac stock because it supports the company’s capacity to finance internal growth initiatives, potential acquisitions and shareholder returns while maintaining a robust balance sheet.

Virbac’s balance sheet remains an important part of the investment case. The group indicated that net debt stood at a manageable level at the end of 2024, with leverage ratios consistent with prudent financial policy for a mid-cap healthcare company. Cash flow from operations was sufficient to cover capital expenditure needs – including investments in manufacturing capacity and R&D – and still provide flexibility for bolt-on transactions in selected markets or product categories. For holders of Virbac stock, this financial profile means the company can continue to invest in innovation without needing to rely excessively on external financing.

Guidance and growth comparison

In terms of guidance, Virbac communicated its expectations for 2025 based on the 2024 performance. The company signaled that it aims to continue growing revenue in the mid single-digit to low double-digit percent range year on year in constant currencies, supported by new product launches, geographical expansion and ongoing demand for existing companion animal and livestock portfolios. This guidance compares with the actual growth delivered in fiscal 2024, which was in the high single-digit area, suggesting a broadly similar or slightly stronger growth ambition in the near term.

Relative to some peers in the global animal health sector, including larger multinational groups, Virbac’s revenue growth in 2024 was competitive. While absolute scale differs, Virbac’s mid to high single-digit revenue increase and margin resilience place it among the companies able to sustain expansion even in an environment of mixed pet ownership trends and farm-sector volatility. For investors analyzing Virbac stock, this comparison underlines that the French group is not merely maintaining its position but actively expanding within its niches, particularly in companion animal therapeutics.

Another quantifiable aspect of the guidance is the company’s targeted EBITDA margin range, which remains in the mid to high teens for 2025. This is broadly consistent with the level achieved in 2024, indicating that management does not foresee substantial margin compression from cost inflation or competitive pressures if volume growth continues as anticipated. Should Virbac manage to lift margins further through efficiency measures and a richer product mix, the upside to earnings and free cash flow could reinforce the support for Virbac stock over time.

Companion animal products support growth

Virbac’s product portfolio is a central driver of its financial performance. In the companion animal space, the group offers a wide range of veterinary medicines and care products for dogs and cats, including dermatology treatments, dental hygiene solutions, vaccines, and parasiticides used to control fleas, ticks and internal parasites. These products are prescribed and recommended by veterinarians and sold through clinical channels and specialized distributors, providing recurring revenue streams as pet owners seek ongoing preventive and therapeutic care for their animals.

The continued expansion of pet ownership in many markets, particularly in Europe and North America, supports Virbac’s growth in companion animal revenue. As more households consider pets part of the family, willingness to spend on veterinary services and medicines typically increases. This trend helped Virbac’s companion animal segment achieve higher sales in 2024 compared with 2023, reinforcing the company’s strategic focus on innovating in indications such as skin conditions, oral health and parasite control. For Virbac stock, the health of this product segment is significant because companion animal treatments often carry attractive margins and brand loyalty.

In livestock, Virbac offers vaccines and pharmaceutical products that contribute to herd health and productivity in cattle, swine, poultry and other farm animals. While livestock revenue growth in 2024 was more moderate than in companion animals, the segment still contributed an important share to total revenue and offers diversification benefits. Farm-animal demand can be cyclical and influenced by commodity price movements, but over the long term, the need for efficient and safe food production supports continued use of professional veterinary products. Virbac’s ability to serve both pet and farm markets positions the group to benefit from structural demand in animal health.

Virbac stock and market valuation

On the equity market, Virbac stock is listed in Paris and belongs to the French mid-cap universe. Market data from recent trading sessions indicate that the company’s shares currently trade at a valuation reflecting both its growth profile and profitability metrics. As of the most recent available date, Virbac’s market capitalization stands in the low to mid EUR billions, consistent with a mid-cap classification and providing sufficient liquidity for institutional and retail investors interested in gaining exposure to the animal health sector.

In terms of share-price development, Virbac stock has historically shown sensitivity to earnings releases, guidance updates and broader sector moves in healthcare and pharmaceuticals. The solid revenue growth in 2024 and improved earnings have supported the stock compared with levels seen in previous periods when growth was slower or visibility was temporarily reduced by specific challenges. Investors often benchmark Virbac’s valuation – for example via price to earnings or enterprise value to EBITDA multiples – against those of larger animal health players to gauge whether the stock trades at a discount or premium relative to its fundamentals and size.

Technical indicators such as 52-week trading ranges and relative performance versus relevant indexes can also be used to contextualize Virbac stock on the market. Over the latest 12-month period, the shares have fluctuated within a range that reflects both general equity market volatility and company-specific news flow. Against this backdrop, the current price level sits relatively close to the mid-point of the 52-week range, suggesting neither extreme optimism nor pronounced pessimism on the part of investors at the time of writing. For long-term holders, the key remains how consistently Virbac can deliver on its growth and margin objectives.